Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.
Jaemin JoSe Hyun KimYu Jung KimJuhyun LeeMiso KimBhumsuk KeamTae Min KimDong Wan KimDae Seog HeoJin Haeng ChungYoon Kyung JeonJong Seok LeePublished in: Yonsei medical journal (2018)
Pemetrexed-based regimens may prolong PFS in patients with ALK+ NSCLC as a first-line treatment, but are not associated with prolonged OS. Exposure to second-generation ALK inhibitors may improve OS rates in patients with ALK+ NSCLC.